Goldman, Jennifer G. http://orcid.org/0000-0001-5014-7535
Forsberg, Leah K.
Boeve, Bradley F.
Armstrong, Melissa J.
Irwin, David J.
Ferman, Tanis J.
Galasko, Doug
Galvin, James E.
Kaufer, Daniel
Leverenz, James
Lippa, Carol F.
Marder, Karen
Abler, Victor
Biglan, Kevin
Irizarry, Michael
Keller, Bill
Munsie, Leanne
Nakagawa, Masaki
Taylor, Angela
Graham, Todd
Article History
Received: 24 August 2020
Accepted: 8 October 2020
First Online: 29 October 2020
Ethics approval and consent to participate
: NA
: NA
: Goldman—Dr. Goldman has received grant/research funding from Michael J. Fox Foundation and Parkinson’s Foundation, served as consultant for Worldwide Med, and has received honoraria from Davis Phinney Foundation, International Parkinson and Movement Disorder Society, and Parkinson’s Foundation.Forsberg—Dr. Forsberg has nothing to disclose.Boeve—Dr. Boeve has received grant/research funding from the NIH (AG016574, AG062677, NS100620, AG056639, AG054256, AG050326), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation and serves as an investigator for clinical trials sponsored by Biogen, Alector, and EIP Pharma; Scientific Advisory Board of the Tau Consortium.Armstrong—Dr. Armstrong has received grant/research funding from AHRQ (K08HS24159), NIA P30AG047266, and the Florida Department of Health (grant 20A08) and compensation from the AAN for work as an evidence-based medicine methodology consultant and is on the level of evidence editorial board for Neurology® and related publications (uncompensated).Irwin—Dr. Irwin has received grant/research funding from NIH NS109260, U01-NS100610, R01-AG056014, P30-AG010124, U19-AG062418, and Penn Institute on Aging.Ferman—Dr. Ferman has nothing to disclose.Galasko—Dr. Galasko has received grant/research funding from NIH/NIA, State of California, and Michael J Fox Foundation and serves as a consultant to Esai, Biogen, Fujirebio, Amprion, vTv Pharmaceuticals, and DSMB for Cognition Therapeutics.Galvin—Dr. Galvin is the creator of the Lewy Body Composite Risk Score.Kaufer—Dr. Kaufer has nothing to report.Leverenz—Dr. Leverenz has received grant/research funding from NIH/NINDS and GE Healthcare and has received consultant fees from Acadia, Eisai, and Sunovion.Lippa—Dr. Lippa has received clinical trial research support from Acadia and Axovant.Marder—Dr. Marder has received grant/research funding from NIH (U01NS100600, U24NA107168, UL1TR001873, R01NS0736 71, R01LM00986, R01NS-9435, RM1HG007257), Michael J. Fox Foundation, Parkinson’s Foundation, CHDI, and Huntington's Disease Society of America.Abler—Dr. Abler is a full-time employee of Acadia Pharmaceuticals.Biglan—Dr. Biglan is a full-time employee and has a minor shareholder stake in Eli Lilly and Company.Irizarry—Dr. Irizarray is a full-time employee of Eisai, Inc.Keller—Mr. Keller is a full-time employee of Acadia Pharmaceuticals.Munsie—Ms. Munsie is a full-time employee and has a minor shareholder stake in Eli Lilly and Company.Nakagawa—Mr. Nakagawa is a full-time employee of Eisai Co., Ltd.Taylor—Ms. Taylor is a full-time employee and Senior Director of Research and Advocacy for the Lewy Body Dementia Association.Graham—Mr. Graham is the Executive Director of the Lewy Body Dementia Association.Drs. Goldman, Boeve, Armstrong, Irwin, Galasko, Galvin, Kaufer, Leverenz, Lippa, and Marder have received grant funding from the Lewy Body Dementia Association Research Center of Excellence program.